BTAI Stock News & Analysis | Latest Updates

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a virtual fireside chat on Thursday, August 14, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. “HCW@Home” series.

August 13, 2025Investor Event

BTAI News

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Bioxcel Therapeutics Announces That An Independent Data Safety Monitoring Board Recommended That The Serenity At-Home Pivotal Phase 3 Safety Trial Of BXCL501 For Acute Treatment of Agitation Associated With Bipolar Disorders Or Schizophrenia Continue With

BioXcel Therapeutics Wins Nasdaq Extension, Has Until September to Regain Listing Compliance

BioXcel Therapeutics Q1 EPS $(1.50) Beats $(4.16) Estimate, Sales $168.00K Miss $426.67K Estimate

BioXcel Therapeutics Q4 2024 GAAP EPS $(3.57) Beats $(6.59) Estimate, Sales $366K Miss $706.667K Estimate

Rodman & Renshaw Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $65

BioXcel Therapeutics Bolsters Cash Reserves To Advance SERENITY At-Home Phase 3 Trial, Topline Data Expected In H2 2025

BioXcel Therapeutics Announces 33% Enrollment In SERENITY At-Home Pivotal Phase 3 Safety Trial For Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia; Topline Data Expected In 2H25

BioXcel Therapeutics Shares Resumed Trade

BioXcel Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 67.6%

BioXcel Therapeutics Announces $14M Registered Direct Offering of 4M Shares Of Common Stock And Accompanying Warrants At A Combined Price Of $3.50

BioXcel Shares Are Up Today: What's Going On?

BioXcel Therapeutics Shares Resume Trade Following Circuit Breaker Halt

BioXcel Therapeutics Announced That The FDA Concluded That The Inspection Of A Single Site In Its TRANQUILITY II Phase 3 Trial And Released The Establishment Inspection Report. The FDA Has Designated Voluntary Action Indicated For The Site

BioXcel Therapeutics Regains Nasdaq Listing Compliance, Overcomes Bid Price Challenge

BioXcel Therapeutics Files For Resale Of Up To 5.1M Shares By The Selling Stockholders

BioXcel Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.60) Estimate, Sales $214.00K Miss $1.31M Estimate

BioXcel Therapeutics Announces First Patient Dosed In TRANQUILITY II Phase 3 Trial For Acute Treatment Of Agitation In Patients With Alzheimer's Disease